Health and Fitness Health and Fitness
Tue, December 2, 2008
[ Tue, Dec 02nd 2008 ] - Market Wire
Biodel to Report Fourth Quarter and Fiscal Year 2008 Financial Results on December 10, 2008
[ Tue, Dec 02nd 2008 ] - Market Wire
FORTIS: Resolutions of the General Meeting of Shareholders held on 1 and 2 December 2008
[ Tue, Dec 02nd 2008 ] - Market Wire
Bard to Host December 2008 Investor Conference
[ Tue, Dec 02nd 2008 ] - Market Wire
Neoprobe Announces Funding Milestone Reached
[ Tue, Dec 02nd 2008 ] - Market Wire
Trinity Biotech: Trinity Biotech Announces US$6m of Cost Reduction Measures
[ Tue, Dec 02nd 2008 ] - Market Wire
Dr. Edmund Pezalla Named President of the Pharmacy and Therapeutics Society
[ Tue, Dec 02nd 2008 ] - Market Wire
Meridian Bioscience Announces Filing of Shelf Reg .. tement to Replace Expiring Registration Statement
[ Tue, Dec 02nd 2008 ] - Market Wire
Helicos BioSciences Corporation Realigns Senior Management Team
[ Tue, Dec 02nd 2008 ] - Market Wire
Corcept Therapeutics: Caroline Loewy Joins Corcept as Chief Financial Officer
[ Tue, Dec 02nd 2008 ] - Market Wire
CLX Medical, Inc.: CLX Medical, Inc. Announces Close of ThyroTest(R) Acquisition
[ Tue, Dec 02nd 2008 ] - Market Wire
Adeona Pharmaceuticals, Inc.: Adeona Pharmaceutic .. Research Institute (NNRI) Collaborate to Test Flu
[ Tue, Dec 02nd 2008 ] - Market Wire
Medtronic Launches Sprinter Angioplasty Balloon Cathethers on Rapid Exchange
[ Tue, Dec 02nd 2008 ] - Market Wire
BioElectronics Announces Positive Clinical Results - Rapid Recovery Breast Augmentation Study
[ Tue, Dec 02nd 2008 ] - Market Wire
Theravance, Inc.: GSK and Theravance Announce Pos .. BA, '444 in the Horizon Asthma Development Progra
[ Tue, Dec 02nd 2008 ] - Market Wire
Northland Resources Inc.: Northland Resources Inc .. g) Concession Granted for Tapuli Iron Ore Project
[ Tue, Dec 02nd 2008 ] - Market Wire
LHC Group Expands Footprint to 16 States with Initial Entry into Oklahoma
[ Tue, Dec 02nd 2008 ] - Market Wire
Metabolic Research, Inc. Expands Broadcast Programs
[ Tue, Dec 02nd 2008 ] - Market Wire
Cubist Pharmaceuticals Names Santosh J. Vetticade .. t, Clinical Development and Chief Medical Officer
[ Tue, Dec 02nd 2008 ] - Market Wire
Protalix BioTherapeutics Announces Completion of .. votal Phase III Clinical Trial of Gaucher Disease
[ Tue, Dec 02nd 2008 ] - Market Wire
Targeted Genetics: Targeted Genetics Realigns Pro .. Priorities and Implements Cost Reduction Measures
[ Tue, Dec 02nd 2008 ] - Market Wire
Oculus Innovative Sciences Announces Agreement wi .. Development of Microcyn Technology Use in Taiwa
[ Tue, Dec 02nd 2008 ] - Market Wire
POZEN To Participate in The RBC Capital Markets 2008 Healthcare Conference
[ Tue, Dec 02nd 2008 ] - Market Wire
NPS Pharmaceuticals Initiates Phase 3 STEPS Stu .. educes Parenteral Nutrition Dependence in Short B
[ Tue, Dec 02nd 2008 ] - Market Wire
XenoPort Reports Results from a Phase 2 Clinical .. nt for the Symptoms of Gastroesophageal Reflux Di
[ Tue, Dec 02nd 2008 ] - Market Wire
SciClone Pharmaceuticals, Inc.: SciClone Pharmace .. ls Appoints Gary Titus as Chief Financial Officer
[ Tue, Dec 02nd 2008 ] - Market Wire
Applied Biosystems " Part of Life Technologies .. spond to Melamine Contamination in Dairy Products
[ Tue, Dec 02nd 2008 ] - Market Wire
VIVUS to Present at J.P. Morgan 2008 SMid Cap Conference
[ Tue, Dec 02nd 2008 ] - Market Wire
BIOLASE Technology, Inc.: BIOLASE Cuts Quarterly Fixed Costs by $2 Million or 20 Percent
[ Tue, Dec 02nd 2008 ] - Market Wire
Titan Pharmaceuticals Announces Reduction in Force
Mon, December 1, 2008
[ Mon, Dec 01st 2008 ] - Market Wire
Endo Pharmaceuticals: Endo Announces Resignation of Board Member

Endo Pharmaceuticals: Endo Announces Resignation of Board Member


Published on 2008-12-01 14:52:31 - Market Wire
  Print publication without navigation


CHADDS FORD, PA--(Marketwire - December 1, 2008) - Endo Pharmaceuticals (NASDAQ: [ ENDP ]) announced today the resignation of George F. Horner, III as a member of the company's board of directors. Mr. Horner has been a director of Endo since August 2006 and has resigned to pursue other business opportunities. The resignation will be effective January 1st, 2009.

"The board and I greatly appreciate George's contributions to Endo's growth and success and wish him well in his future endeavors," said David Holveck, president and chief executive officer of Endo.

Endo Pharmaceuticals will immediately begin the search for a new member to join the board of directors.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. More information, including this and past press releases of Endo Pharmaceuticals is available at [ www.endo.com ].

Contributing Sources